Evidence map›Paper›PMID 32926203›Full record

ArticleEuropean journal of clinical pharmacology2021

Effects of a multifaceted intervention to promote the use of intravenous iron sucrose complex instead of ferric carboxymaltose in patients admitted for more than 24 h.

Justine Touchard, G Perrin, S Berdot, J Pouchot, M C Loustalot, B Sabatier

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Justine TouchardPharmacy Department, Georges-Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris, 20 rue Leblanc, 75015, Paris, France. justinetouchard@hotmail.fr.ORCID https://orcid.org/0000-0001-6573-8506
G PerrinPharmacy Department, Georges-Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris, 20 rue Leblanc, 75015, Paris, France.
S BerdotPharmacy Department, Georges-Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris, 20 rue Leblanc, 75015, Paris, France.
J PouchotInternal Medicine Department, Georges-Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
M C LoustalotPharmacy Department, Georges-Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris, 20 rue Leblanc, 75015, Paris, France.
B SabatierPharmacy Department, Georges-Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris, 20 rue Leblanc, 75015, Paris, France.
Hôpital Européen Georges-Pompidou · FRInserm · FRUniversité Paris-Sud · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAlthough more practical for use, the impact of ferric carboxymaltose (FCM) on the hospital budget is considerable, and intravenous iron sucrose complex (ISC) represents a cost-saving alternative for the management of iron deficiency anemia in patients during hospitalization. The Drug Committee decided to reserve FCM for day hospitalizations and contraindications to ISC, especially allergy. ISC was available for prescription for all other situations.

methodsThe impact of a multifaceted intervention promoting a switch from FCM to ISC was evaluated using an interrupted time series model with segmented regression analysis. The standardized rate of the dispensing of FCM, ISC, and oral iron by the hospital pharmacy, as well as the rate of the dispensing of packed red blood cells and the number of biological iron status measurements, was analyzed before and after the intervention.

resultsThere was an immediate decrease in FCM consumption following the intervention, with a reduction of 88% (RR: 0.12 [CI

conclusionOur intervention to lower the impact of intravenous iron therapy on the hospital budget was effective.

Indexed as

Administration, OralAnemia, Iron-DeficiencyCost-Benefit AnalysisCost SavingsDecision Support Systems, ClinicalDrug PrescriptionsFerric CompoundsFerric Oxide, SaccharatedFranceHealth Plan ImplementationHematinicsHospital CostsHospitalizationHumansInfusions, IntravenousInterrupted Time Series Analysisferric carboxymaltoseFerric CompoundsFerric Oxide, SaccharatedHematinicsIronMaltoseClinical practice guidelineGeneral practiceHealthcare quality improvement

Identifiers

PMID32926203
OpenAlexW3086175997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.